Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 8.
doi: 10.1111/aos.17590. Online ahead of print.

Real-world outcomes of aflibercept 8 mg in patients previously treated for neovascular age-related macular degeneration

Imadeddin Abu Ishkheidem  1   2 , Esra Inci  2 , Martin Breimer  2 , Sofia Töyrä Silfverswärd  1   2 , Madeleine Zetterberg  1   2 , Marita Andersson Grönlund  1   3
Affiliations

Real-world outcomes of aflibercept 8 mg in patients previously treated for neovascular age-related macular degeneration

Imadeddin Abu Ishkheidem et al. Acta Ophthalmol. .

Abstract

Purpose: To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age-related macular degeneration (nAMD).

Methods: This retrospective study included nAMD patients switched to aflibercept 8 mg from prior anti-VEGF therapies at Sahlgrenska University Hospital between February 2024 and February 2025. Data on best-corrected visual acuity (BCVA), central retinal thickness (CRT), pigment epithelial detachment (PED) height, fluid status, treatment intervals, time to fluid recurrence and adverse events were collected.

Results: 181 eyes (167 patients; mean age 80.4 ± 8.5 years; 67.7% female) were included, with a median follow-up of 12.9 weeks (range 4.1-48.1). A total of 415 injections were administered (mean 2.1 ± 1.5 per eye). BCVA remained stable (baseline 0.46 ± 0.31 logMAR; post-treatment 0.47 ± 0.37 logMAR; p = 0.18). CRT decreased significantly (-19.5 ± 47.2 μm; p < 0.001), as did PED height (-37.4 ± 68.4 μm; p < 0.001). Intraretinal fluid prevalence decreased from 34.3% to 19.3% (p < 0.001) and subretinal fluid from 53.0% to 33.7% (p < 0.001). The median maximal dry interval achieved was nine weeks, and analysis of interval extension showed a statistically significant mean increase of 1.27 ± 4.24 weeks overall (p = 0.0009), particularly in eyes dry at baseline. The median time to fluid recurrence among those with reactivation was ten weeks. Higher baseline CRT predicted greater CRT reduction (-44.1 μm per 100 μm increase; p < 0.001) but shorter dry intervals. Safety was favourable, with one case (0.6% per eye; 0.2% per injection) of mild anterior uveitis and no cases of intraocular pressure elevation.

Conclusions: Switching to aflibercept 8 mg led to stable vision, significant anatomical improvements, extended treatment intervals and a favourable short-term safety profile. Longer follow-up is warranted.

Keywords: aflibercept; age‐related macular degeneration; ocular inflammation; optical coherence tomography; real‐world data.

PubMed Disclaimer

References

REFERENCES

    1. Bala, S., Barbosa, G.C.S., Mohan, N., Srivastava, S.K., Kaiser, P.K., Sastry, A. et al. (2025) Initial functional and anatomical outcomes of high‐dose aflibercept 8 mg in exudative neovascular age‐related macular degeneration. Ophthalmol Retina, 9, 756–766. Available from: https://doi.org/10.1016/j.oret.2025.02.002
    1. European Commission (2024) Eylea 8 mg (aflibercept) – marketing authorisation. Union Register of medicinal products for human use. Accessed 6 Sep 2025, at: https://ec.europa.eu/health/documents/community‐register/html/h797.htm.
    1. Ferris, F.L., Wilkinson, C.P., Bird, A., Chakravarthy, U., Chew, E., Csaky, K. et al. (2013) Clinical classification of age‐related macular degeneration. Ophthalmology, 120, 844–851.
    1. Guymer, R.H., Markey, C.M., McAllister, I.L., Gillies, M.C., Hunyor, A.P. & Arnold, J.J. (2019) Tolerating subretinal fluid in neovascular age‐related macular degeneration treated with ranibizumab using a treat‐and‐extend regimen: FLUID study 24‐month results. Ophthalmology, 126, 723–734.
    1. Hashiya, N., Maruko, I., Miyaguchi, Y., Maruko, R., Hasegawa, T. & Iida, T. (2025) Intraocular inflammation after intravitreal injection of aflibercept 8 mg for treatment‐refractory neovascular age‐related macular degeneration: a case report. BMC Ophthalmology, 25, 42.

LinkOut - more resources